The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Therapeutics Development Initiative, 2008Novel Gastric Retentive Controlled-release Dosage Forms of Levodopa/Carbidopa: in vivo Assessment in Pre-Clinical Models
Objective/Rationale:
The objective of this project is to develop gastric retentive controlled-release tablets of levodopa/carbidopa that will result in more constant blood levels of levodopa compared... -
Therapeutics Development Initiative, 2008Passive Immunotherapy for Parkinson's Disease based on Naturally Occurring Autoantibodies against alpha-Synuclein
Objective/Rationale:
We suggest a novel approach for the treatment of Parkinson's disease based on anti-alpha-synuclein monoclonal antibodies. This treatment concept offers a preventive approach in... -
Therapeutics Development Initiative, 2008Discovery of Novel Inhibitors of LRRK2 for the Treatment of Parkinson's Disease
Objective/Rationale:
A recent breakthrough in Parkinson’s disease research is the discovery that mutations in the gene for leucine-rich repeat kinase 2 (LRRK2) are associated with both the hereditary... -
Therapeutics Development Initiative, 2008GPR88, a new PD target involved in the modulation of basal ganglia circuitry
The receptor GPR88 is highly expressed in brain areas relevant for Parkinson's disease. GPR88 is an orphan receptor, i.e., a receptor with no known ligands. The neurobiological role and signalling...
-
Therapeutics Development Initiative, 2008Spectroscopy of Human Plasma for Diagnosis of Idiopathic Parkinson's Disease
Objective/Rationale:
The diagnosis of Parkinson disease is based on clinical criteria and is labor-intensive, expensive and often inconclusive. Unfortunately, there are currently no accepted...
-
Therapeutics Development Initiative, 2008Hif Prolyl Hydroxylase Inhibitors: New Treatment Potential against Parkinson's Disease
Hif prolyl hydroxylase (HPH) has been identified as one of the genes regulated in the brains of Parkinson’s disease patients. Recent research data suggest that HPH is involved in the mechanism...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.